Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3628 | Simvastatin Wiki | 0.71 |
| drug1965 | Interferon-Beta Wiki | 0.50 |
| drug1783 | Hydroxychloroquine + lopinavir/ritonavir Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug332 | Apixaban 2.5 MG Wiki | 0.50 |
| drug1541 | Five-days oseltamivir Wiki | 0.50 |
| drug333 | Apixaban 5MG Wiki | 0.50 |
| drug2271 | Macrolide administered for 3-5 days Wiki | 0.50 |
| drug1544 | Fixed-duration Hydrocortisone Wiki | 0.50 |
| drug3952 | Ten-days oseltamivir Wiki | 0.50 |
| drug3056 | Prasugrel Wiki | 0.50 |
| drug3125 | Protocolised mechanical ventilation strategy Wiki | 0.50 |
| drug271 | Amoxicillin-clavulanate Wiki | 0.50 |
| drug808 | CUROSURF® (poractant alfa) Wiki | 0.50 |
| drug1968 | Interferon-β1a Wiki | 0.50 |
| drug861 | Ceftaroline Wiki | 0.50 |
| drug4015 | Ticagrelor Wiki | 0.50 |
| drug2913 | Piperacillin-tazobactam Wiki | 0.50 |
| drug2272 | Macrolide administered for up to 14 days Wiki | 0.50 |
| drug2166 | Lopinavir-Ritonavir Drug Combination Wiki | 0.50 |
| drug2440 | Moxifloxacin or Levofloxacin Wiki | 0.50 |
| drug3615 | Shock-dependent hydrocortisone Wiki | 0.50 |
| drug862 | Ceftriaxone Wiki | 0.50 |
| drug1545 | Fixed-duration higher dose Hydrocortisone Wiki | 0.50 |
| drug1415 | Eritoran Wiki | 0.50 |
| drug3989 | Therapeutic anticoagulation Wiki | 0.35 |
| drug942 | Clopidogrel Wiki | 0.29 |
| drug340 | Apremilast Wiki | 0.29 |
| drug3701 | Standard Care Wiki | 0.25 |
| drug3532 | Sarilumab Wiki | 0.22 |
| drug3384 | Rivaroxaban Wiki | 0.22 |
| drug2176 | Losartan Wiki | 0.17 |
| drug274 | Anakinra Wiki | 0.17 |
| drug2174 | Lopinavir/ritonavir Wiki | 0.16 |
| drug963 | Colchicine Wiki | 0.14 |
| drug4249 | Vitamin C Wiki | 0.13 |
| drug1060 | Convalescent plasma Wiki | 0.11 |
| drug4025 | Tocilizumab Wiki | 0.08 |
| drug1775 | Hydroxychloroquine Wiki | 0.05 |
| drug2916 | Placebo Wiki | 0.02 |
Navigate: Correlations HPO
There are 4 clinical trials
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic resulting in critical illness. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19.
Description: Primary end-point for patients with suspected or proven COVID-19 pandemic infection
Measure: Days alive and not receiving organ support in ICU Time: Day 21Description: EQ5D-5L and WHODAS 2.0 (not completed in all regions)
Measure: Health-related Quality of life assessment Time: 6 monthsDescription: Characterised as home, rehabilitation hospital, nursing home or long-term care facility, or another acute hospital
Measure: Destination at time of hospital discharge Time: Free text Day 90Description: Antibiotic Domain specific outcome
Measure: Occurrence of multi-resistant organism colonisation/infection Time: Day 90, censored at hospital dischargeDescription: Antibiotic Domain specific outcome
Measure: Occurrence clostridium difficile Time: Day 90, censored at hospital dischargeDescription: Macrolide Duration domain specific outcome, and COVID-19 Antiviral Domain specific outcome.
Measure: Occurrence of serious ventricular arrhythmia (including ventricular fibrillation) or sudden unexpected death Time: Day 90, censored at hospital dischargeDescription: Antiviral Domain specific outcome. Only required at selected sites.
Measure: Change from baseline influenza virus levels in upper and lower respiratory tract specimens Time: Day 3, up to Day 7Description: COVID-19 Antiviral Domain and COVID-19 Immune Modulation Domain specific endpoint
Measure: Serial detection of SARS-CoV-2 in upper or lower respiratory tract specimens (using only specimens collected for routine clinical testing) Time: Day 90, censored at hospital dischargeACT is a randomized clinical trial to assess therapies to reduce the clinical progression of COVID-19.
Description: composite of hospitalization or death
Measure: Outpatient trial - Colchicine vs. control and Aspirin vs. control Time: 45 days post randomizationDescription: invasive mechanical ventilation or death
Measure: Inpatient trial - Interferon-β vs. control and Colchicine vs. control Time: 45 days post randomizationDescription: invasive mechanical ventilation or death
Measure: Inpatient trial - Aspirin and rivaroxaban vs. control Time: 45 days post randomizationDescription: disease progression by 2 points on a 7-point scale
Measure: Outpatient and Inpatient trials - Colchicine vs. control, Interferon-β vs. control Time: 45 days post randomizationDescription: composite of major adverse cardiovascular events (MI, stroke, ALI, VTE, death), and disease progression by 2 points on a 7-point scale
Measure: Outpatient and Inpatient trials - Aspirin vs. control, Aspirin and rivaroxaban vs. control Time: 45 days post randomizationThe CRASH-19 trial is a multinational, open-label, factorial, randomised trial in adults hospitalised with suspected or confirmed acute COVID-19 infection.
Description: Cause of death will be described
Measure: Death Time: up to 28 days of randomisationA multi-center adaptive randomized placebo-controlled platform trial evaluating the efficacy and safety of anti-thrombotic strategies in COVID-19 adults not requiring hospitalization at time of diagnosis
Description: The primary outcome will be a composite endpoint of need for hospitalization for cardiovascular/pulmonary events, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, ischemic stroke, and all-cause mortality for up to 45 days after initiation of assigned treatment.
Measure: Hospitalization for cardiovascular/pulmonary events Time: 45 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports